ArticleCarcinogenesis2011
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.
Article in Carcinogenesis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pharmacogenetic Association betweenBioMed research international · 2020Pooled it
- Genetic factors associated with iron storage in Australian blood donors.Blood transfusion = Trasfusione del sangue · 2018Trial
- Significance of Lipopolysaccharides in Gastric Cancer and Their Potential as a Biomarker for Nivolumab Sensitivity.International journal of molecular sciences · 2023Article
- Exploring the mechanism of aidi injection for lung cancer by network pharmacology approach and molecular docking validation.Bioscience reports · 2021Article
- Genetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer.Carcinogenesis · 2017Article
- Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.Biochemical Society transactions · 2016Review
- Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance.Cell cycle (Georgetown, Tex.) · 2016Article
- Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study.Scientific reports · 2015Article
- Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells.Anticancer research · 2014Article
- Article
- Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas.Seminars in radiation oncology · 2013Review
- Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.Cancer research · 2013Article
- Association between single nucleotide polymorphisms of the transforming growth factor-β1 gene and overall survival in unresectable locally advanced non-small-cell lung cancer patients treated with radio(chemo)therapy in a Chinese population.Medical oncology (Northwood, London, England) · 2013Article
- Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Current topics in medicinal chemistry · 2013Review
- SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer.PloS one · 2012Article
- Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The magnitude of benefit is variable for advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy. The purpose of this study is to determine whether genetic variations in the transforming growth factor-beta (TGF-β) pathway are associated with clinical outcomes in NSCLC patients receiving first-line platinum-based chemotherapy. Five hundred and ninety-eight advanced-stage NSCLC patients who received first-line platinum-based chemotherapy with or without radiotherapy were recruited at the MD Anderson Cancer Center between 1995 and 2007. DNA from blood was genotyped for 227 single nucleotide polymorphisms (SNPs) in 23 TGF-β pathway-related genes to evaluate their associations with overall survival. In individual SNP analysis, 22 variants were significantly associated with overall survival, of which the strongest associations were found for BMP2:rs235756 [hazard ratio (HR) = 1.45; 95% confidence interval (CI), 1.11-1.90] and SMAD3:rs4776342 (HR = 1.25; 95% CI, 1.06-1.47). Fifteen and 18 genetic loci displayed treatment-specific associations for chemotherapy and chemoradiation, respectively, identifying a majority of the cases who would be predicted to respond favorably to a specific treatment regimen. BMP2:rs235753 and a haplotype in SMAD3 were associated with overall survival for both treatment modalities. Cumulative effect analysis showed that multiple risk genotypes had a significant dose-dependent effect on overall survival (P(trend) = 2.44 x 10(-15)). Survival tree analysis identified subgroups of patients with dramatically different median survival times of 45.39 versus 13.55 months and 18.02 versus 5.89 months for high- and low- risk populations when treated with chemoradiation and chemotherapy, respectively. These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.